Valuation: Filana Therapeutics, Inc.

Market Cap 31.79M 28.47M 26.27M 23.77M 44.45M 3.03B 45.17M 313M 125M 1.58B 119M 117M 5.02B P/E 2026 *
-0.74x
P/E 2027 * -0.55x
Enterprise Value 31.79M 28.47M 26.27M 23.77M 44.45M 3.03B 45.17M 313M 125M 1.58B 119M 117M 5.02B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.95%
Yield 2026 *
-
Yield 2027 * -
1 day+1.12%
1 week+0.60%
Current month-25.73%
1 month-28.84%
3 months-24.33%
6 months-54.31%
Current year-66.77%
1 week 0.6
Extreme 0.6007
0.68
1 month 0.6
Extreme 0.6007
1.04
Current year 0.6
Extreme 0.6007
2.49
1 year 0.6
Extreme 0.6007
3.45
3 years 0.6
Extreme 0.6007
42.2
5 years 0.6
Extreme 0.6007
100
10 years 0.6
Extreme 0.6007
146.16
Manager TitleAgeSince
Chief Executive Officer 67 06/09/2024
Director of Finance/CFO 57 01/10/2018
Chief Tech/Sci/R&D Officer 70 07/08/2025
Director TitleAgeSince
Director/Board Member 78 07/12/2007
Chairman 67 17/07/2024
Chairman 74 09/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
29/09/26 Buy

Chief Executive Officer

206,813 0.4281%
28/09/26 Buy

Chief Executive Officer

93,091 0.1927%
24/11/25 Buy

Director

8,600 0.0178%
Change 5-day change 1-year change 3-year change Capi.($)
+1.12%+0.60%-80.76%-96.69% 31.43M
+0.34%+1.12%+34.75%+61.06% 64.14B
+0.98%+2.68%+12.25%+82.98% 55.53B
+1.75%+2.01%+13.30%+103.69% 53.03B
-1.43%-1.17%+26.27%+52.86% 45.99B
-0.48%-2.80%+18.01%+117.99% 42.45B
+0.82%+1.37%+227.94%+922.41% 40.45B
-0.26%-2.57%+12.55%+45.18% 32.25B
-2.07%+42.73%+103.77%+88.74% 34.47B
-2.57%-4.19%+19.96%-13.11% 24.23B
Average -0.18%+3.92%+38.80%+136.51% 39.26B
Weighted average by Cap. -0.07%+3.59%+49.09%+160.40%

Financials

2026 *2027 *
Net sales - -
Net income -43.76M -39.19M -36.16M -32.72M -61.18M -4.17B -62.17M -431M -172M -2.18B -164M -161M -6.91B -60M -53.74M -49.58M -44.87M -83.9M -5.71B -85.25M -592M -236M -2.99B -225M -220M -9.47B
Net Debt - -
Projected Income Statement - Annual - Filana Therapeutics, Inc.
Logo Filana Therapeutics, Inc.
Filana Therapeutics, Inc., formerly Cassava Sciences, Inc., is a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Employees
19
Date Price Change Volume
29/10/26 $0.6580 +1.12% 264,599
28/10/26 $0.6507 +0.37% 347,434
27/10/26 $0.6483 +5.97% 295,675
26/10/26 $0.6118 -3.73% 297,215
23/10/26 $0.6355 -2.84% 313,552
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Filana Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.6580USD
Average target price
6.500USD
Spread / Average Target
+887.84%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Filana Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. FLNA Stock